SWAV Stock Recent News

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion amid JNJ entering into a definitive agreement to acquire the company.

Although the revenue and EPS for Shockwave Medical (SWAV) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Shockwave Medical (SWAV) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.03 per share a year ago.

Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In the latest trading session, Shockwave Medical (SWAV) closed at $328.99, marking a +0.04% move from the previous day.

Shockwave Medical (SWAV) concluded the recent trading session at $329, signifying a +0.45% move from its prior day's close.

Shockwave Medical (SWAV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

We have narrowed our search to five high-flying Nasdaq Composite listed non-tech stocks with more upside left. These are: CELH, SWAV, COIN, HOOD, IBKR.

Shockwave Medical (SWAV) announces the 'real-world' results of the REDUCER-I study, which is intended to collect long-term outcomes on Shockwave Reducer, a novel treatment for refractory angina.

On April 5, 2024, Johnson & Johnson NYSE: JNJ announced its intent to acquire Shockwave Medical Inc. NASDAQ: SWAV for $13.1 billion. Under the terms of the proposed deal, JNJ will pay $335 per share, which is a 4.75% premium compared to Shockwave's closing price on April 4, 2024.